Evidence map›Paper›PMID 36045703›Full record

ArticleExploration of targeted anti-tumor therapy2021

Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center.

Maristella Bungaro, Valentina Bertaglia, Marco Audisio, Elena Parlagreco, Chiara Pisano, Valeria Cetoretta, Irene Persano, Francesca Jacobs, Chiara Baratelli, Lorena Consito and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Maristella BungaroMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Valentina BertagliaMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Marco AudisioMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Elena ParlagrecoMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Chiara PisanoMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Valeria CetorettaMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Irene PersanoMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Francesca JacobsMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Chiara BaratelliMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Lorena ConsitoMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Maria Lucia RealeMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Fabrizio TabbòMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Paolo BironzoMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.
Giorgio Vittorio ScagliottiMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.ORCID https://orcid.org/0000-0001-6646-958X
Silvia NovelloMedical Oncology, San Luigi Gonzaga University Hospital, University of Torino, 10043 Orbassano, Italy.ORCID https://orcid.org/0000-0001-7653-9748
Ospedale San Luigi Gonzaga · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensure optimal care, especially in frail groups such as cancer patients (pts). This study investigated the efficacy of SARS-CoV-2 pre-procedure screening and whether COVID-19 influenced timely diagnosis and therapy. Methods: Data of oncological procedures of pts with confirmed or suspected cancer diagnosis, treated at Oncology Department or coming from Emergency Department of San Luigi Gonzaga Hospital between June 2020 and March 2021 were retrospectively collected. A nasopharyngeal swab (NPS) was performed in outpatients 24/48 h before procedures. Inpatients were tested by NPS before and after hospitalization. Results: Two hundred and twenty-one pts were included in this analysis. Median age was 73 years, males were 58%. Eastern Cooperative Oncology Group (ECOG) Performance Status was 0 or 1 in 88% of pts. The most frequent cancer type was lung cancer (57%). Stages IV were 77%. Two hundred and forty-three scheduled procedures were performed with diagnostic ( Conclusions: SARS-CoV-2 infection led to the postponement of a small, but not negligible percentage of oncological procedures. However, the low infection rate observed suggests that structured screening for COVID-19 is critical for the best management of scheduled procedures during pandemic.

Indexed as

cancer careCOVID-19diagnosisoncological proceduresprevention

Identifiers

PMID36045703
PMCPMC9400781
OpenAlexW3208247893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.